利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.014 秒)

    Pharmaceutical use of pyridoxal derivative
    1.
    发明授权
    Pharmaceutical use of pyridoxal derivative 失效
    药物使用吡哆醛衍生物

    公开(公告)号：US5441972A

    公开(公告)日：1995-08-15

    申请号：US222596

    申请日：1994-04-04

    申请人： Kazumi Ogata ,  Shunji Sogo ,  Eri Inoue

    发明人： Kazumi Ogata ,  Shunji Sogo ,  Eri Inoue

    IPC分类号： A61K31/44

    CPC分类号： A61K31/44 ,  Y10S514/912

    摘要： A novel use of the compound of the formula ##STR1## wherein R.sub.1 is hydrogen atom or lower alkyl and R.sub.2 is hydrogen atom or phosphoric acid group, or a pharmacologically acceptable salt thereof for preventing and treating cataract. The compounds of the formula (I) and pharmacologically acceptable salts thereof of the present invention inhibit initial changes in the lens, such as vacuolation and trochoidal change, and almost completely inhibit a decrease in the amounts of reduced glutathione and cysteine in the lens, so that they are advantageously used for the prevention of the onset and progress of cataract.

    摘要翻译： 其中R 1为氢原子或低级烷基且R 2为氢原子或磷酸基团的式（I）化合物或其药理学上可接受的盐用于预防和治疗白内障的新用途。 本发明的式（I）化合物及其药理学上可接受的盐抑制透镜的初始变化，例如空泡化和摆线变化，并且几乎完全抑制透镜中还原型谷胱甘肽和半胱氨酸的量的降低，因此 它们有利地用于预防白内障的发作和进展。

    Pharmaceutical composition
    2.
    发明授权
    Pharmaceutical composition 失效
    药物组成

    公开(公告)号：US5871739A

    公开(公告)日：1999-02-16

    申请号：US729152

    申请日：1996-10-11

    申请人： Eri Inoue

    发明人： Eri Inoue

    IPC分类号： A61K38/00 ,  C07K14/47 ,  C07K16/18 ,  A61K39/00

    CPC分类号： C07K16/18 ,  C07K14/47 ,  A61K38/00

    摘要： A pharmaceutical composition comprising, as an active ingredient, a lens antigen which induces a lens cell damaging immune response or a microorganism capable of expressing a lens antigen which induces a lens cell damaging immune response. The pharmaceutical composition of the present invention containing, as an active ingredient, a lens antigen or a microorganism capable of expressing said antigen shows markedly superior inhibitory effects on the increase of an anti-lens protein antibody titer. Therefore, it most probably treats or prevents cataract effectively, and delays onset of cataract. Thus, the composition is extremely useful for cataract patients and reserve patients of cataract.

    摘要翻译： 一种药物组合物，其包含作为活性成分的诱发晶状体细胞损伤免疫应答的晶状体抗原或能够表达镜片抗原的微生物，其诱导晶状体细胞损伤免疫应答。 含有透镜抗原或能够表达所述抗原的微生物作为活性成分的本发明的药物组合物对抗晶状体蛋白抗体滴度的增加显示出显着优异的抑制作用。 因此，它最有可能有效治疗或预防白内障，并延缓白内障发作。 因此，该组合物对白内障患者和白内障预留患者非常有用。

    Agent for therapeutic treatment of optic nerve diseases and the like
    3.
    发明授权
    Agent for therapeutic treatment of optic nerve diseases and the like 失效
    用于治疗视神经疾病的药剂等

    公开(公告)号：US07638516B2

    公开(公告)日：2009-12-29

    申请号：US11477854

    申请日：2006-06-30

    申请人： Tomiya Mano ,  Shunji Sogou ,  Eri Inoue

    发明人： Tomiya Mano ,  Shunji Sogou ,  Eri Inoue

    IPC分类号： A01N43/58

    CPC分类号： A61K31/00 ,  A61K31/4152

    摘要： The medicament for therapeutic and/or prophylactic treatment of the present invention has a suppressing action on the retinal degeneration induced by transient retinal ischemia, which is verified by the results for suppressing effect on retinal degeneration in transient retinal ischemia eye. Therefore, the medicament of the present invention has a therapeutic and/or prophylactic effectiveness on diseases in optic nerve and the like.

    摘要翻译： 用于本发明治疗和/或预防治疗的药物对由视网膜短暂性视网膜缺血引起的视网膜变性具有抑制作用，其通过抑制视网膜缺血眼视网膜变性的效果的结果来验证。 因此，本发明的药物对视神经等疾病具有治疗和/或预防效果。